Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Biotech company developing a chemogenetic gene therapy platform for neurological diseases, focused on severe pain and epilepsy.
CODA Biotherapeutics was a South San Francisco, California-based biotechnology company that developed a chemogenetic gene therapy platform designed to treat complex neurological diseases. The preclinical-stage enterprise engineered specialized receptors controlled by synthetic drugs rather than natural neurotransmitters to selectively modify neuronal cell populations, initially targeting severe chronic neuropathic pain and epilepsy. Before officially ceasing its corporate operations in March 2023 under the leadership of Chief Executive Officer Michael Narachi, the firm raised $34 million in total venture funding. This capitalization included a $19 million Series A financing round led by MPM Capital and Versant Ventures, alongside strategic participation from corporate investors Astellas Venture Management and Novartis. These financial resources were utilized to advance therapeutic candidates for chronic pain conditions affecting more than 19 million Americans. CODA Biotherapeutics was founded in 2018 by Joseph Glorioso and Dr. Nicholas Boulis.
CODA Biotherapeutics has raised $62.7M across 4 funding rounds.
CODA Biotherapeutics has raised $62.7M in total across 4 funding rounds.
CODA Biotherapeutics has raised $62.7M in total across 4 funding rounds.
CODA Biotherapeutics's investors include David Stack, MPM Capital, Versant Ventures, National Institute of Neurological Disorders and Stroke, Astellas Venture Management, Tom Woiwode, Todd Foley, Graham Walmsley, Shunichiro Matsumoto, Ricardo Dolmetsch.
CODA Biotherapeutics has raised $62.7M across 4 funding rounds. Most recently, it raised $28.0M Other Equity in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2021 | $28M Venture Round | David Stack | MPM Capital, Versant Ventures | Announced |
| Nov 10, 2020 | $670K Grant | National Institute OF Neurological Disorders And Stroke | — | Announced |
| Nov 5, 2019 | $15M Venture Round | — | Astellas Venture Management, MPM Capital, TOM Woiwode | Announced |
| Sep 17, 2018 | $19M Series A | Todd Foley, Graham Walmsley | Shunichiro Matsumoto, Ricardo Dolmetsch | Announced |